TY  - JOUR 
AU  - San Miguel Izquierdo, Jesús Fernando
AU  - Schlag, Rudolf
AU  - Khuageva, Nuriet K
AU  - Dimopoulos, Meletios A.
AU  - Shpilberg, Ofer
AU  - Kropff, Martin
AU  - Spicka, Ivan
AU  - Petrucci, Maria T
AU  - Palumbo, Antonio
AU  - Samoilova, Olga S
AU  - Dmoszynska, Anna
AU  - Abdulkadyrov, Kudrat M
AU  - Schots, Rik
AU  - Jiang, Bin
AU  - Mateos Manteca, María Victoria
AU  - Anderson, Kenneth C
AU  - Esseltine, Dixie-Lee
AU  - Liu, Kevin
AU  - Cakana, Andrew
AU  - van de Velde, Helgi
AU  - Richardson, Paul G.
PY  - 2008
UR  - http://hdl.handle.net/10366/154297
AB  - [EN]The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated...
LA  - eng
KW  - Mieloma múltiple
KW  - Disease Progression
KW  - Aged
KW  - Boronic Acids
KW  - Follow-Up Studies
KW  - Humans
KW  - Pyrazines
KW  - Melphalan
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Time Factors
KW  - Treatment Outcome
KW  - Prednisone
KW  - Survival Analysis
TI  - Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
DO  - 10.1056/NEJMoa0801479
T2  - New England journal of medicine
VL  - 359
M2  - 906
ER  -